Affimed (AFMD) gave an update at the ASH conference this weekend for their AFM13 program in both monotherapy and combination with NK. The monotherapy data was a disappointment, while the NK combination continued to provide promising updates.
AFM13 Monotherapy Data
This was a Phase-2 study using AFM13 as a monotherapy in patients with relapsed/refractory p…